Anti-prolactin autoantibodies in paediatric systemic lupus erythematosus patients

Abstract

The aim of this study was to determine the frequency of anti-prolactin autoantibodies and the relationship among anti-prolactin autoantibodies, serum prolactin (PRL) levels and lupus activity in paediatric patients with systemic lupus erythematosus (SLE) using a transversal study. One-hundred and three consecutive paediatric SLE patients were tested for serum anti-PRL autoantibodies and PRL levels. Clinical disease activity was scored using the SLEDAI index. Anti-PRL autoantibodies were measured by means of gel filtration. The frequency of anti-PRL autoantibodies was 6.7% (7=103), on the basis of the amount of immunoreactive PRL eluted in molecular weight fraction corresponding to IgG (150 kDa). No anti-PRL autoantibodies were found in normoprolactinaemic patients. By contrast, 21.8% (7=32) hyperprolactinaemic patients (hPRL) had anti-PRL autoantibodies. There was a correlation between anti-PRL autoantibody and serum levels of PRL (r_s ¹/4 0.98, P ¹/4 0.0001). Lupus activity was present in 64=103(62.1%) patients, without a significant difference in the frequency of anti-PRL autoantibodies when compared to inactive lupus (7.8 vs5.1%, P > 0.05). Higher levels of serum PRL were associated with lupus activity regardless of other variables (39.6% vs 17.9%, P ¹/4 0.05). Patients with anti-PRL autoantibodies had higher levels of serum PRL than those without anti-PRL autoantibody (41.85 vs 17.77 ng/ml, P ¹/4 0.01) and significantly different frequency of hPRL (100 vs 26%, r ¹/4 0.4531, P< 0.001). We have identified a subset of paediatric SLE patients with hPRL and anti-PRL autoantibodies. Anti-PRL autoantibodies were associated with hPRL state and antibody titres correlated positively with serum PRL levels. These data suggest that anti-PRL autoantibodies could be responsible for hPRL in a subset of SLE patients. An increase in serum PRL levels proved to be related to lupus activity, but there was no statistical relationship between anti-PRL autoantibodies and lupus activity.

Keywords

prolactin anti-prolactin autoantibody hyperprolactinaemia disease activity

Get full access to this article

View all access options for this article.

References

Lahita RG . Systemic lupus erythematosus. In: Lahita RG (ed). Textbook of the Autoimmune Disease. Lippincor Williams & Wilkins: Philadelphia, USA , 2000, pp 537–548.

Blanco F , Kalsi J , Isenberg DA . Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic disease . Clin Exp Immunol 1991; 86: 66–70 .

Blanco F , Kalsi J , Ravirajan CT , Speit P , Bradwell AR , Isenberg DA . IgG subclasses in systemic lupus erythematosus and other rheumatic disease . Lupus 1992; 1: 391–399 .

Berezil I . The immunology of prolactin . Semin Reprod Endocrinol 1992; 10: 196–219 .

Spangelo BL , Hall NR , Ross PC , Goldstein AL . Stimulation of in vivo antibody production and concanavalin-A-induced mouse spleen cell mitogenesis by prolactin . Immunopharmacology 1987; 14: 11–20 .

Berczi I , Nagy E . The effect prolactin and growth hormone on hemolymphopoetic tissue and immune function. In: Kovacs K (ed). Hormones and Immunity. MTP Press: Norwell , 1987, pp 145–170.

Cross RJ , Campbell JL , Rozsman TI . Potentiation of antibody responsiveness after the transplantation of a syngenic pituitary gland . J Neuroimmunol 1989; 25: 29–35 .

McMurray R , Keisler D , Kanuekel K , Izui S , Walker SE . Prolactin influences autoimmune disease activity in the female B/W mouse . J Immunol 1991; 147: 780–787 .

Smith PE . The effect of hypophysectomy upon the involution of the thymus in the rat . Anac Rec 1930; 47: 119–129 .

10.

Nagy E , Berczi I . Immunodeficiency in hipophysectomized rats . Acta Endocrinol 1978; 89: 530–537 .

11.

Nagy E , Berczi I , Friesen HG . Regulation of immunity in rats by lactogenic and growth hormones . Acta Endocrinol (Copenh) 1983; 102: 351–357 .

12.

Nagy E , Berezi I , Wren GE , Asa SL , Kovaks K . Immunomodulation by bromocriptine . Immunopharmacology 1983; 6: 231–243 .

13.

Lavalle C , Loyo E , Paniagua R . Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus . J Rheumatol 1987; 14: 268–272 .

14.

Folomeev M , Prokaeva T , Nassonova V . Prolactin levels in men with SLE and RA . J Rheumatol 1990; 17: 1569–1570 .

15.

Pauzner R , Urowitz MB , Gladman DD . Prolactin levels in systemic lupus erythematosus . (Abstract). Arthritis Rheum 1992; 35: S239-S239 .

16.

Jara LJ , Gomez-Sanchez C , Silveira LH , Martinez-Osuna P , Vassey FB , Espinoza LR . Hyperprolactinemia in systemic lupus erythematosus: association with disease activity . Am J Med Sci 1992; 303: 222–226 .

17.

Davis WE , Quinet R , Winters E et al. Serum interleukin 6 (IL 6) and prolactin (PRL) do not correlate with disease activity in systemic lupus erythematosus (SLE) . (Abstract). Lupus 1995; 4(Suppl 2): S67-S67 .

18.

Buskila D , Lorber M , Neumann L , Flusser D , Shoenfeld Y . No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus . J Rheumatol 1996; 23: 629–632 .

19.

Pauzner R , Urowitz MB , Gladman DD , Cough J . Prolactin in systemic lupus erythematosus . J Rheumatol 1994; 21: 2064–2067 .

20.

Neidhart M . Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases . J Rheumatol 1996; 23: 476–481 .

21.

Batrinos ML , Panitsa-Faflia C , Tsiganou E , Liapi C . Incidence and characteristics of microprolactinomas (3–5 mm) in 4199 women assayed for prolactin . Horm Metab Res 1992; 24: 384–391 .

22.

Athreya BH , Rafferty JH , Sehgal GS , Lahita RG . Adenohypophyseal and sex hormone in paediatric rheumatic disease . J Rheumatol 1993; 20: 725–730 .

23.

Barile L , Jara LJ , Graef A , Lavelle C . Sex hormone and childood SLE .J Rheumatol 1994; 21: 5-5 .

24.

Graf AE , Salah S , Shaarawy M , Zaki S , Anwer S . Prolactin hormone in juvenil systemic lupus erithematosus. A possible relationship to disease activity and CNS manifestation . J Rheumatol 1996; 23: 374–377 .

25.

Allen SH , Sharp GC , Wang G et al. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease . Lupus 1996; 5: 30–37 .

26.

Ostendorf B , Fischer R , Santen R , Schmitz-Linneweber B , Specker Ch , Schneider M . Hyperprolactinemia in systemic lupus erythematosus? Scand J Rheumatol 1996; 25: 97–102 .

27.

Blanco-Favela F , Quintal-Alvarez G , Leaños-Miranda A . Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power . J Rheumatol 1999; 26: 55–59 .

28.

Conconi MV , Walker AM . Chloroquine affects prolactin secretion and golgi morphology in the mammotroph . Endocrinology 1984; 114: 725–734 .

29.

Hattori N , Ishihara T , Ikekubo K , Moridera K , Hino M , Kurahachi H . Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia . J Clin Endocrinol Metab 1992; 75: 1226–1229 .

30.

Hattori N , Ikekubo K , Ishihara T , Moridera K , Hino M , Kurahachi H . Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody . Eur J Endocrinol 1994; 130: 438–445 .

31.

Leaños A , Pascoe D , Fraga A , Blanco-Favela F . Anti-prolactin auto-antibodies in systemic lupus erythematosus patients with associated hyperprolactinemia . Lupus 1998; 7: 398–403 .

32.

Tan EM , Cohen AS , Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

33.

Bombardier C , Gladman D , Urowitz M , Caron D , Chang CH and The Committee on Prognosis Studies in SLE . Derivation of the SLEDAI: a disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

34.

Vance ML , Thorner MO . Prolactin: hyperprolactinemic syndromes and management, In: De Groot LJ (ed). Endocrinology, 2nd edn. WB Saunders: Philadelphia, PA , 1989, p 408-408.

35.

Leaños-Miranda A , Pascoe-Lira D , Blanco-Favela F . Prolactin and systemic lupus erythematosus . (Letter.) Br J Rheuamtol 1998; 37: 1029–1030 .

36.

Llorente L , Zou W , Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus . J Exp Med 1995; 181: 839–844 .

37.

Hattori N , Ikekubo K , Ishihara T , Moridera K , Hino M , Kurahachi H . Effects of anti-prolactin autoantibodies on serum prolactin measurements . Eur J Endocrinol 1994; 130: 434–437 .

38.

Sievertsen GD , Lim VS , Nakawatase C , Frohmn LA . Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure . J Clin Endocrinol Metab 1980; 50: 846–852 .

39.

Hattori N , Inagaki C . Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-Immunoglobulin G Complex . J Clin Endocrinol Metab 1997; 82: 3107–3110 .

40.

McMurray RW , Allen SH , Braun AL , Rodriguez F , Walker SE . Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune dis-ease . J Rheumatol 1994; 21: 843–850 .

41.

Rabinovich CE , Schanberg LE , Kredich DW . Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric systemic lupus erythematosus . (Abstract.) Arthritis Rheum 1990; 33: R22-R22 .

42.

McMurray RW , Weidensaul D , Allen SH , Walker S . Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus . J Rheumatol 1995; 22: 2084–2091 .